L-Ornithine L-Aspartate

We are L-Ornithine L-Aspartate CAS:3230-94-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


L-Ornithine L-Aspartate
 
An aspartate salt of L-ornithine. L-Ornithine L-aspartate has been shown to reduce blood ammonia concentrations by increasing ammonia detoxification in the liver and reducing the severity of hepatic encephalopathy in cirrhosis.

Cas.No 3230-94-2
Assay 98.0-101.0%
Description White crystals or crystalline powder, odorless, slightly acid taste
Status Infusion
Applications Dietary Supplement
Packaging 25kg&50kg
STORAGE Controlled room temperature in tight container.
Keep in dark.

 
SPECIFICATION AND PROCEDURE

State of solution
(Transmittance)
Not Less Than 98.0%
pH 5.0~6.0
Specific rotation[α]20D +26.9~+28.9°
Ammonium (NH4) Not More Than 0.020%
Chloride content (Cl) Not More Than 0.020%
Sulfate (SO4) Not More Than 0.020%
Iron (Fe) Not More Than 10 ppm
Heavy metals (Pb) Not More Than 10 ppm
Arsenic (As2O3) Not More Than 1 ppm
Loss on drying Not More Than 3.0%
Residue on ignition Not More Than 0.20%
Related substances Not More Than 0.4%
Endotoxin* Less Than 6.0 EU/g
Assay (dry basis) 98.0~101.0%

· * The endotoxin-certified grade will be supplied on request.
 

L-Ornithine L-Aspartate


Related News: API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.3-Chloro-1-propanol CAS:627-30-5 API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.clorhidrato de clorometilo CAS:22128-62-7 The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.2-cianoisonicotinato de metilo CAS:94413-64-6 The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.

Related Products
Product Name
D-Valine View Details
TRIPHENYL PHOSPHATE (TPP) View Details
2-Bromo-5-chloroanisole View Details
perfluorohexanoic acid Cas:307-24-4 manufacturer N-butyl pyridinium bis(trifluoromethyl sulfonyl)imide manufacturer Methyl 2-hydroxy-5-nitrobenzoate manufacturer 1,1,1-Tris(diphenylphosphino)methane manufacturer N-Cbz-glycine Ethyl Ester manufacturer